Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Neutral Sentiment
“Project Optimus encourages optimal biological dosing rather than maximally tolerated dosing.” — Harry Erba, MD, PhD
Key Takeaway: The article features a quote from Harry Erba, MD, PhD, discussing Project Optimus, which emphasizes the importance of optimal biological dosing over maximally tolerated dosing. However, the article does not provide further details or context about the project or its implications.
Price reaction · baseline $12.3 (2023-12-15 close) · 3 other KURA headline(s) in the window, move may be shared
day 0 close · peak
+0.4%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic